Lumida
/HTFL
⌘K
HTFL

HTFL

HTFL
$49.88USD↑+9.65%+4.39 today

MARKET CAP

4.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$46 – $50

52W RANGE

$20
$52

AI Summary

Stalk
Buy NowMedium

The recent momentum breakout above the prior resistance has driven a strong rally, and price has reclaimed and is tightly tracking above rising EMAs after a shallow pullback, confirming demand dominance. Medium-term structure remains bullish with higher highs and higher lows intact, supported by volume and EMA alignment. Short-term execution is favorable as price holds above EMAs and RSI sits in a constructive mid-range. A failure to hold the 9- and 20-day EMAs or a deeper retracement below the 50-day SMA would invalidate the bullish posture, while a break above prior highs would reinforce continuation.

  • ↑Q2 2026 revenue $64.1M (+48% YoY) with second consecutive growth acceleration.
  • ↑Asymptomatic patient segment could unlock an additional $6B market by 2030.
  • ↓Q2 net loss $5.8M narrowed from $17.6M a year ago but remains unprofitable.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

HeartFlow, Inc. (NASDAQ: HTFL) operates in the cardiovascular diagnostics sector, specializing in AI-driven solutions for detecting, diagnosing, and managing coronary artery disease (CAD). Through innovative technologies such as its flagship Fractional Flow Reserve CT (FFRCT) and Plaque Analysis (PLAC), HeartFlow aims to transform cardiovascular diagnostics. Positioned in a rapidly evolving market, HeartFlow is targeting a total addressable market estimated at $11 billion, focusing on both symptomatic and high-risk asymptomatic populations.

Bull says

  • ↑Q2 2026 revenue $64.1M (+48% YoY) with second consecutive growth acceleration.
  • ↑Asymptomatic patient segment could unlock an additional $6B market by 2030.
  • ↑Non-GAAP gross margin expected ~82% in 2026 driven by AI-automation efficiencies.
  • ↑Cash balance of $254.9M funds R&D and rollout of new PCI Navigator tool.
  • ↑200M+ annotated CT images database strengthens competitive moat and accuracy.
  • ↑Positive growth and analyst revision factors plus moderate leverage support stability.

Bear says

  • ↓Q2 net loss $5.8M narrowed from $17.6M a year ago but remains unprofitable.
  • ↓Challenges converting revenue to profit underscore persistent profitability pressure.
  • ↓Early adoption cycle demands extensive physician education, risking slower uptake.
  • ↓Competition from GE, Siemens, Philips and Abbott may pressure pricing and share.
  • ↓High volatility and negative short interest reflect investor skepticism.
  • ↓Negative earnings yield and low institutional holdings suggest weak returns.

Investment themes with HTFL

Health Care Providers↓ -0.37%

UNH · CVS · HCA

Earnings Call · Q3 2025 · Mgmt. Guidance

Updated 08-18-2026neutral

Transcript signals

Bull points

  • tremendous amount of operating flexibility to invest opportunistically down the P&L.
  • get the company to profitability within three years of IPO.
  • Total revenue was $46.3 million, up 41%.

Bear points

  • Operating loss was $11.1 million compared to $12.6 million last year.
  • Non-GAAP net loss was $13.2 million or 27 cents per share compared to non-GAAP net loss of $16.2 million or $2.90 per share in the third quarter of 2024.
  • On a GAAP basis, net loss was $50.9 million, or $1.04 per share, versus $19.1 million, or $3.43 per share, last year.
Read full transcript analysis ›